PCP
VRTX icon

Proficio Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Proficio Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+2,184
New +$968K 0.04% 191
2025
Q3 		– Sell
-1,955
Closed -$870K – 427
2025
Q2 		$870K Sell
1,955
-124
-6% -$57.1K 0.05% 171
2025
Q1 		$1.01M Buy
2,079
+1,101
+113% +$513K 0.08% 129
2024
Q4 		$394K Buy
978
+311
+47% +$144K 0.03% 226
2024
Q3 		$310K Sell
667
-179
-21% -$86K 0.03% 213
2024
Q2 		$397K Buy
846
+23
+3% +$9.98K 0.04% 198
2024
Q1 		$344K Buy
823
+34
+4% +$14.4K 0.04% 222
2023
Q4 		$321K Sell
789
-4
-0.5% -$1.48K 0.04% 213
2023
Q3 		$276K Buy
793
+73
+10% +$25.5K 0.04% 231
2023
Q2 		$253K Buy
720
+32
+5% +$10.8K 0.03% 243
2023
Q1 		$217K Buy
+688
New +$206K 0.03% 265
2020
Q4 		– Sell
-757
Closed -$206K – 197
2020
Q3 		$206K Buy
757
+22
+3% +$6.07K 0.04% 163
2020
Q2 		$213K Buy
+735
New +$199K 0.04% 157
2019
Q3 		– Sell
-333
Closed -$61K – 1503
2019
Q2 		$61K Buy
333
+14
+4% +$2.45K 0.02% 317
2019
Q1 		$59K Buy
319
+66
+26% +$12.2K 0.02% 298
2018
Q4 		$42K Sell
253
-5
-2% -$866 0.02% 342
2018
Q3 		$50K Buy
258
+8
+3% +$1.43K 0.02% 356
2018
Q2 		$42K Buy
250
+10
+4% +$1.55K 0.02% 403
2018
Q1 		$39K Sell
240
-8
-3% -$1.31K 0.01% 418
2017
Q4 		$37K Sell
248
-52
-17% -$7.7K 0.01% 423
2017
Q3 		$46K Buy
300
+19
+7% +$2.86K 0.02% 399
2017
Q2 		$44K Buy
281
+31
+12% +$3.73K 0.02% 411
2017
Q1 		$29K Buy
250
+172
+221% +$15.1K 0.01% 520
2016
Q4 		$6K Buy
78
+7
+10% +$570 ﹤0.01% 727
2016
Q3 		$6K Buy
71
+13
+22% +$1.23K ﹤0.01% 691
2016
Q2 		$6K Buy
58
+54
+1,350% +$4.67K ﹤0.01% 671
2016
Q1 		$0 Sell
4
-41
-91% -$3.71K ﹤0.01% 1172
2015
Q4 		$6K Buy
+45
New +$5.43K 0.01% 397

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Proficio Capital Partners's VRTX Position: Q2 2026 in Review

Proficio Capital Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 2,184 shares worth $1.08M. The stake represents 0.04% of the portfolio and ranks #191 among its holdings. This is a return to the name: Proficio Capital Partners previously reported a position in VRTX as recently as Q2 2025.

Proficio Capital Partners first reported a position in VRTX in Q4 2015 and has held it in 28 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Proficio Capital Partners held 2,184 shares of Vertex Pharmaceuticals worth $1.08M as of Q2 2026.
  • Vertex Pharmaceuticals was a new Proficio Capital Partners position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.04% of Proficio Capital Partners's portfolio in Q2 2026, its #191 holding.
  • Proficio Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Proficio Capital Partners's 13F filing for Q2 2026, filed 17 Aug 2026.